diphenhydramine has been researched along with Rectal Neoplasms in 1 studies
Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.
diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.
antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
Rectal Neoplasms: Tumors or cancer of the RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a patient with metastatic colon cancer who developed a hypersensitivity reaction to oxaliplatin during the sixth cycle of combination chemotherapy with oxaliplatin, high-dose 5-fluorouracil and leucovorin." | 1.32 | Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. ( Chang, MC; Chang, YF; Hsieh, RK; Huang, MJ; Lim, KH; Lin, HC; Lin, J; Su, YW, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lim, KH | 1 |
| Huang, MJ | 1 |
| Lin, HC | 1 |
| Su, YW | 1 |
| Chang, YF | 1 |
| Lin, J | 1 |
| Chang, MC | 1 |
| Hsieh, RK | 1 |
1 other study available for diphenhydramine and Rectal Neoplasms
| Article | Year |
|---|---|
Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Desen | 2004 |